Effect of sodium glucose cotransporter 2 inhibitors on obstructive sleep apnea in patients with type 2 diabetes

Kei Sawada; Shigehiro Karashima; Mitsuhiro Kometani; Rie Oka; Yoshimichi Takeda; Toshitaka Sawamura; Aya Fujimoto; Masashi Demura; Ayako Wakayama; Mikiya Usukura; Kunimasa Yagi; Yoshiyu Takeda; Takashi Yoneda

doi:10.1507/endocrj.EJ17-0440

ORIGINAL

Effect of sodium glucose cotransporter 2 inhibitors on obstructive sleep apnea in patients with type 2 diabetes

Kei Sawada, Shigehiro Karashima, Mitsuhiro Kometani, Rie Oka, Yoshimichi Takeda, Toshitaka Sawamura, Aya Fujimoto, Masashi Demura, Ayako Wakayama, Mikiya Usukura, Kunimasa Yagi, Yoshiyu Takeda, Takashi Yoneda

Author information

Kei Sawada
Division of Endocrine and Diabetes, Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan
Shigehiro Karashima
Division of Endocrine and Diabetes, Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan
Mitsuhiro Kometani
Division of Endocrine and Diabetes, Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan
Rie Oka
Division of Endocrine and Diabetes, Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan
Yoshimichi Takeda
Division of Endocrine and Diabetes, Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan
Toshitaka Sawamura
Division of Endocrine and Diabetes, Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan
Aya Fujimoto
Division of Endocrine and Diabetes, Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan
Masashi Demura
Department of Hygiene, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan
Ayako Wakayama
Department of Internal Medicine, Houju Memorial Hospital, Ishikawa 923-1226, Japan
Mikiya Usukura
Department of Internal Medicine, Houju Memorial Hospital, Ishikawa 923-1226, Japan
Kunimasa Yagi
Division of Endocrine and Diabetes, Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan
Yoshiyu Takeda
Division of Endocrine and Diabetes, Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan
Takashi Yoneda
Division of Endocrine and Diabetes, Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Ishikawa 920-8641, Japan
Program management office for Paradigms Establishing Centers for Fostering Medical Researchers of the Future, Kanazawa University, Ishikawa 920-8641, Japan
Institute of Liberal Arts and Science, Kanazawa University, Ishikawa 920-8641, Japan

Keywords: Sodium glucose cotransporter 2 inhibitors, Obstructive sleep apnea syndrome, Type 2 diabetes

JOURNAL FREE ACCESS FULL-TEXT HTML
Supplementary material

2018 Volume 65 Issue 4 Pages 461-467

DOI https://doi.org/10.1507/endocrj.EJ17-0440

Browse “Advance online publication” version

Details

Abstract

Obstructive sleep apnea syndrome (OSAS) is often associated with metabolic disorders such as obesity and type 2 diabetes and may contribute to cardiovascular events. A novel class of antidiabetic drugs, the sodium glucose cotransporter 2 inhibitors (SGLT2i) reduce body weight (BW), although there is limited data on their impact on OSAS. We therefore evaluated the effect of SGLT2i on OSAS in patients with type 2 diabetes. The presented study was a retrospective design in 18 patients with type 2 diabetes with OSAS (4 males, age range 39–81 yr) administrated a SGLT2i. HbA1c, BW, body mass index (BMI), blood pressure (BP) and apnea hypopnea index (AHI) were evaluated before and after SGLT2i administration. The relationships between the reduction in AHI and the other variables were examined using Pearson correlation analysis. We have got result that SGLT2i reduced AHI from 31.9 ± 18.0 to 18.8 ± 11.5 events per hr (p = 0.003). HbA1c, BW and BMI decreased significantly, whereas BP did not. The Pearson correlation analysis showed a significant relationship between the reduction in AHI and pre-administration of AHI. In conclusion, SGLT2i reduced not only HbA1c, BW and BMI but also AHI significantly and therefore has potential as an effective treatment of OSAS.

Corresponding author

Register with J-STAGE for free!